Chief Commercial Officer — Todd Edwards: The filing discloses the appointment of a new external Chief Commercial Officer, which is a significant addition to the management team but not a departure.

Results of Operations and Financial Condition. On August 10, 2026, Oruka Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report. The information in this Item 2.02, including Exhibit 99.1 to this report, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or other…

Other Events. On April 28, 2026, the Company entered into an Underwriting Agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC, Stifel, Nicolaus & Company, Incorporated and Guggenheim Securities, LLC, as the representatives of the several underwriters named in Schedule A thereto (the “Underwriters”), providing for the offering and sale by the Company of 9,660,000 shares of common stock, par value $0.001 per share (the “Common Sto…

solely because it was disclosed in the preliminary prospectus supplement relating to the Offering. This preliminary estimate is based on currently available information and is subject to revision based upon, among other things, the finalization and closing of the Company’s accounting books and records. The Company’s financial results for the three months ended March 31, 2026 are not yet finalized. The preliminary financial data included in the prospectus supplement was prepared by, and is the…

Other Events. On April 27, 2026, Oruka announced results from its Phase 2a EVERLAST-A clinical trial of ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-A Phase 2a Key 16-Week Results The Phase 2a EVERLAST-A clinical trial is a randomized, double-blind, placebo-controlled study evaluating ORKA-001 in patients with moderate-to-severe PsO. EVERLAST-A enrolled 84 patients randomized 3:1 to receive 600 mg of ORKA-001 at Weeks 0 and 4 or matching placebo. The primary endpoint is PASI 100…

Director — Cameron Turtle: Cameron Turtle resigned as a member of the Board of Directors.

Entry into a Material Definitive Agreement. On September 17, 2025, Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). The closing of the Private Placement occurred on September 19, 2025. Pursuant to the Purchase Agreement, the Purchasers purchased (i…

Unregistered Sales of Equity Securities. To the extent required by Form 8-K, the disclosures in

Regulation FD Disclosure. On September 17, 2025, the Company made available a press release announcing the Private Placement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Also on September 17, 2025, the Company made available a press release announcing certain clinical data from its Phase 1 clinical trial of ORKA-001, as well as upcoming scientific presentations at the European Academy of Dermatology and Venereology Congress. A copy of the press…

Chief Operating Officer — Laura Sandler: Ms. Sandler was promoted to Chief Operating Officer from her previous role as Senior Vice President of Operations.

Entry into a Material Definitive Agreement. IL-17A/F (ORKA-002) License Agreement – Paragon Therapeutics, Inc. On February 4, 2025, Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), and Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), entered into a license agreement (the “License Agreement”), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodi…

Entry into a Material Definitive Agreement. IL-23 (ORKA-001) License Agreement – Paragon Therapeutics, Inc. On December 17, 2024, Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), and Paragon Therapeutics, Inc., a Delaware corporation (“Paragon”), entered into a license agreement (the “License Agreement”), pursuant to which Paragon granted the Company a royalty-bearing, world-wide, exclusive license to develop, manufacture, commercialize or otherwise exploit certain antibodies…

Amended employment agreements for severance benefits and payments were signed.

Regulation FD Disclosure. On September 11, 2024, the Company made available a press release announcing the Private Placement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Also on September 11, 2024, the Company made available a press release announcing updated pipeline progress and timelines, as well as an upcoming scientific presentation at the European Academy of Dermatology and Venereology Congress. A copy of the press release is furnished as…

Entry into a Material Definitive Agreement. On September 11, 2024, Oruka Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). The closing of the Private Placement is expected to occur on September 13, 2024. Pursuant to the Purchase Agreement, the Purchasers…

Unregistered Sales of Equity Securities. To the extent required by Form 8-K, the disclosures in

Other Events. On August 26, 2024, ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), issued the press release attached hereto as Exhibit 99.1 and incorporated by reference herein announcing an update regarding the special cash dividend amount in connection with the proposed merger (the “ Merger ”) with Oruka Therapeutics, Inc. (“ Oruka ”), which will now equal $1.613 per share of ARCA’s common stock, par value $0.001 per share (“ Common Stock ”), payable on August 28, 2024 to ARCA’s sto…

Other Events. Following receipt of stockholder approval of all stockholder proposals at the Special Meeting, and as previously disclosed, the Merger is expected to be consummated on August 29, 2024, subject to the satisfaction of the remaining closing conditions under the Merger Agreement. Following approval of the Reverse Stock Split Amendment at the Special Meeting, on August 22, 2024, the ARCA Board of Directors approved the reverse stock split at a ratio of 1-for-12 shares of Common Stock…

Other Events. As previously disclosed, on April 3, 2024, ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) pursuant to which, among other matters, and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Atlas Merger Sub Corp, a Delaware corporation and wholly owned subsidiary of ARCA (“ First Merger Sub ”), will merge with and into Oruka Therapeutics, Inc. (…

Entry into a Material Definitive Agreement. On August 14, 2024, ARCA biopharma, Inc., a Delaware corporation (“ ARCA ”), entered into an asset purchase agreement (the “ Asset Purchase Agreement ”) with Genvara Biopharma, Inc., a Colorado corporation (the “ Buyer ”), pursuant to which the Buyer has agreed to purchase, assume and accept from ARCA all of the rights, title and interest in, to and under the assets, interests and liabilities exclusively related to the business of ARCA as conducted…

of this report and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing. No Offer or Solicitation This Current Report on Form 8-K and the exhibits filed or furnished herewith are not intended…

Entry into a Material Definitive Agreement. Amendment to Subscription Agreement On July 3, 2024, Oruka Therapeutics, Inc., a Delaware corporation (“ Oruka ”), and certain parties entered into a Letter Agreement (the “ Amendment ”), amending that certain Subscription Agreement, dated April 3, 2024, by and among Oruka and each of the purchasers thereto (as amended from time to time, the “ Subscription Agreement ”) that was entered into in connection with the Agreement and Plan of Merger and Reo…

of this report and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing. No Offer or Solicitation This Current Report on Form 8-K and the exhibits filed or furnished herewith are not intended…

Thomas A. Keuer and C. Jeffrey Dekker: The board approved an increase in the retention bonus for two executives.

President, Chief Executive Officer, Director — Michael Bristow, M.D.: Dr. Michael Bristow mutually agreed to conclude his employment and service as a director.